Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions.
about
Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsisBeta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropeniaBeta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsisBeta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropeniaStructural analysis of a putative aminoglycoside N-acetyltransferase from Bacillus anthracis.Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trialsBeta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis.Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatmentAminoglycoside resistance rates, phenotypes, and mechanisms of Gram-negative bacteria from infected patients in upper Egypt.Beneficial antimicrobial effect of the addition of an aminoglycoside to a β-lactam antibiotic in an E. coli porcine intensive care severe sepsis modelMonotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study.Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearanceCombination therapy for treatment of infections with gram-negative bacteria.Better prophylaxis against surgical site infection with local as well as systemic antibiotics. An in vivo study.Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistance.Exploring Synergy between Classic Mutagens and Antibiotics To Examine Mechanisms of Synergy and Antibiotic Action.Aminoglycosides: current role in antimicrobial therapy.In vitro activity and killing effect of DX-8739, a new carbapenem, compared with those of meropenem and imipenem against multiresistant Pseudomonas aeruginosa.Efficacy of ceftazidime and aztreonam alone or in combination with amikacin in experimental left-sided Pseudomonas aeruginosa endocarditis.Effect of concomitant administration of piperacillin on the dispositions of isepamicin and gentamicin in patients with end-stage renal disease.Use of empiric antimicrobial therapy in neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee.Novel Microdilution Method to Assess Double and Triple Antibiotic Combination Therapy In Vitro.In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains.Management of aminoglycosides in the intensive care unit.Circadian variation in serum amikacin levels.Antibiotic combination efficacy (ACE) networks for a Pseudomonas aeruginosa model.
P2860
Q24201201-B4739B88-F3F9-40B4-8E5C-CE6CA29E4D56Q24201767-B1AB7FE6-5F6E-43A3-BAB0-7DC146484D3AQ24244685-91654D34-5F2B-4EA5-9CFF-0A6150C3EC47Q24248048-EDECECCA-6848-4C6A-BBE8-C4268FDAADA6Q27667916-83FC7C19-6510-423A-813B-A1F05880F638Q30756968-F33CFF0B-C96E-4C81-80F6-8E18E2BB5756Q31143077-A0CFDE50-07CD-4D87-A2C5-2980ADB701E7Q33722082-AE079A1A-6B74-43DF-92D5-F2F1A871BED1Q33831880-D1537AE7-E957-428B-8082-41E8EAED4F01Q35109053-70549618-2F24-4C5D-B48A-9EAFBDA2599FQ35136181-C03EFC99-418C-42BC-9234-FC9210F9D624Q35635810-51D6BEF5-13F5-48D3-AE69-28A6CC1E1A84Q36089167-2CB81765-7468-4205-ABA7-4C9EA3907CF1Q36156077-8A2ECE14-1E7E-4FD3-A7F7-367087CF14B2Q37272599-EEBEDB8D-8EB3-4BF2-BA96-D9785516F89AQ37538623-CFADAE9E-E765-47CB-BFF3-F2291AFEF94EQ37563029-7B82F43E-A741-4EFF-A943-AB6ED1BF5E0EQ38028573-9629B22A-0641-4550-A08D-9DD3AAA99E20Q38741524-A9DBE0F7-58A5-4CD3-A8D5-CA2E55F0BA94Q39608639-A2F09B0E-5F22-40C9-B804-C38C0050C638Q39779381-01C627B4-0128-4DA4-80ED-B5611DFE75DEQ39865002-387D9AFC-1098-49B8-936E-D84DF14F9AC9Q39881756-C15B1F93-1E89-4396-AD20-2CF0F9F63DCEQ40335979-DCF09045-450D-4194-8018-97485DA98928Q40668393-BAB6384C-2CDC-49ED-9843-4A9D73909813Q42004511-8E02E515-CCE6-4265-B026-1B5A9C1050D4Q42908869-DCF6B3B3-E8BB-4853-ACE9-F875D70B65DEQ46145943-D2E3BC34-4741-4CD5-B7D7-4BD73A24008CQ53690104-1BF1BB58-8D3B-46EC-A051-54DB9D7C9D99
P2860
Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
1986年论文
@zh
1986年论文
@zh-cn
name
Aminoglycosides plus beta-lact ...... rgy and chemical interactions.
@en
Aminoglycosides plus beta-lact ...... rgy and chemical interactions.
@nl
type
label
Aminoglycosides plus beta-lact ...... rgy and chemical interactions.
@en
Aminoglycosides plus beta-lact ...... rgy and chemical interactions.
@nl
prefLabel
Aminoglycosides plus beta-lact ...... rgy and chemical interactions.
@en
Aminoglycosides plus beta-lact ...... rgy and chemical interactions.
@nl
P1476
Aminoglycosides plus beta-lact ...... rgy and chemical interactions.
@en
P304
P356
10.1016/0002-9343(86)90490-0
P407
P577
1986-06-01T00:00:00Z